生物发明公司的BI-1808显示,在用减少肿瘤和良好耐受性来治疗CTCL方面,早期前景良好。 BioInvent's BI-1808 showed early promise in treating CTCL with tumor reductions and good tolerability.

生物发明组织报告了其实验药物BI-1808在2025年美国血病学学会年会上在治疗皮肤T细胞淋巴瘤(CTCL)方面的试验结果。 BioInvent reported early Phase 2a trial results for its experimental drug BI-1808 in treating cutaneous T-cell lymphoma (CTCL) at the 2025 American Society of Hematology (ASH) annual meeting. 数据表明临床活动迹象良好,包括一些病人肿瘤减少和疾病稳定。 The data showed promising signs of clinical activity, including tumor reductions and disease stabilization in some patients. 该药物是针对CD26的单克隆抗体,一般在没有新的安全顾虑的情况下被很好地推广。 The drug, a monoclonal antibody targeting CD26, was generally well-tolerated with no new safety concerns. 成果支持继续发展BI-1808作为CTCL病人的潜在治疗选择。 Results support continued development of BI-1808 as a potential treatment option for CTCL patients.